United States

Invion Ltd (IVX.AX)

IVX.AX on Australia Stock Exchange

8:04pm EDT
Change (% chg)

$0.00 (+0.00%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Chart for


Invion Limited is a clinical-stage life sciences (drug development) company. The Company is engaged in the completion of clinical development programs and targeted business development programs associated with its approximately three drug assets, such as INV102 (nadolol), INV103 (ala-Cpn10) and INV104 (zafirlukast). It focuses... (more)
No analyst recommendations are available for .


Beta: 2.22
Market Cap(Mil.): $7.28
Shares Outstanding(Mil.): 1,455.96
Dividend: --
Yield (%): --


  Industry Sector
P/E (TTM): -- 60.89 15.95
EPS (TTM): -- -- --
ROI: -- 0.19 15.19
ROE: -- 2.32 13.87

BRIEF-Invion seeks trading halt

* Seeks trading halt pending ASX's determination as to whether company will be required to comply with ASX listing rules Source text for Eikon: Further company coverage:

Sep 01 2017

BRIEF-Invion entered into a series of agreements with Cho Group Limited

* It has entered a series of agreements with Cho Group Limited

Aug 31 2017

BRIEF-Invion Ltd anounces strategic alliance with The Cho Group

* cho group will make an equity investment via placement of 17.69% of existing shares

Apr 17 2017

Earnings vs. Estimates

No consensus analysis data available.